Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Dementia Treatment Market

Dementia Treatment Market Share

Report ID: GMI9342
Published Date: May 2024
Report Format: PDF

Download Free Sample

Dementia Treatment Market Share

The dementia treatment industry is characterized by a diverse landscape of pharmaceutical companies, biotechnology firms, and research organizations vying for market share. Established players in market holds significant positions with their approved medications targeting cognitive symptoms, while newer entrants and academic institutions contribute to innovation with novel therapeutic approaches. Market share dynamics are influenced by factors such as product efficacy, safety profile, pricing strategies, regulatory approvals, and market access, driving competition and market segmentation across regions and therapeutic segments within the market.

Dementia Treatment Market Companies

Prominent players operating in the dementia treatment industry include:

AbbVie Inc.
Biogen
Cipla Inc.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly and Company
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The dementia treatment market was valued at USD 17.7 billion in 2023 and is expected to exhibit growth at 7.6% CAGR from 2024

The cholinesterase inhibitors segment in the dementia treatment industry generated USD 8 billion in 2023, owing to ongoing research efforts focused on improving the efficacy, safety, and tolerability of ChEIs.

North America dementia treatment market size was USD 6.7 billion in 2023 and is anticipated to grow at 7.4% CAGR between 2024

AbbVie Inc., Biogen, Cipla Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., Novartis AG and Otsuka Pharmaceutical Co., Ltd.